Over the past year there were no insider purchases at Catalyst Pharmaceuticals, Inc.. Three insiders sold roughly $1.8 million instead.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Looking at the quarterly pattern: No open-market insider buying or selling in the last full quarter. Insiders bought in 0 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Dec 16, 2025 | Harper Molly | Director | Sell | 4,473 | $23.73 | $106K | SEC |
| Dec 16, 2025 | Harper Molly | Director | Sell | 15,527 | $23.20 | $360K | SEC |
| Dec 16, 2025 | Harper Molly | Director | Sell | 6,746 | $23.06 | $156K | SEC |
| Nov 28, 2025 | Del Carmen Jeffrey | Executive Officer | Sell | 10,983 | $23.33 | $256K | SEC |
| Nov 14, 2025 | Elsbernd Brian | Executive Officer | Sell | 40,000 | $22.70 | $908K | SEC |
| Sep 10, 2025 | Elsbernd Brian | Executive Officer | Sell | 30,000 | $20.30 | $609K | SEC |
| Sep 5, 2025 | Elsbernd Brian | Executive Officer | Sell | 30,000 | $19.52 | $586K | SEC |
| Sep 5, 2025 | Elsbernd Brian | Executive Officer | Sell | 20,000 | $20.08 | $402K | SEC |
| Aug 28, 2025 | Tierney David S | Director | Sell | 26,000 | $20.20 | $525K | SEC |
| Aug 28, 2025 | Miller Steve | Executive Officer | Sell | 115,000 | $20.28 | $2.3M | SEC |
| Aug 28, 2025 | Daly Richard J | CEO | Sell | 22,970 | $20.62 | $474K | SEC |
| Jun 12, 2025 | Sundaram Preethi | Executive Officer | Sell | 2,324 | $26.41 | $61K | SEC |
| Jun 12, 2025 | Sundaram Preethi | Executive Officer | Sell | 1,600 | $26.42 | $42K | SEC |
| Jun 10, 2025 | MCENANY PATRICK J | Director | Sell | 171,748 | $26.11 | $4.5M | SEC |
| Jun 10, 2025 | MCENANY PATRICK J | Director | Sell | 28,252 | $25.95 | $733K | SEC |
In the last 12 months Catalyst Pharmaceuticals, Inc. insiders made open-market purchases worth about $0 and sales worth about $1.8 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in CPRX was filed on 2025-12-16.
No congressional trades in CPRX were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).